Key result
Left ventricular reverse remodeling after anterior STEMI is linked to non-significantly lower MACE.
Observational (n=40)
No
Absolute Event Rate: 0% vs 36%
p-value: p=0.07
LV reverse remodeling occurs at a relatively high rate in patients with anterior STEMI treated with primary PCI and optimal pharmacotherapy.
LV reverse remodeling may aid post-anterior STEMI risk stratification; leaves open its role as modifiable target or surrogate.
INTRODUCTION: The study aimed to evaluate the prevalence and predictors of left ventricular (LV) reverse remodeling and its impact on long-term prognosis in patients with anterior ST-segment elevation myocardial infarction (STEMI). AIM: To assess the percentage of reverse remodeling and its prognostic factors in anterior STEMI patients. MATERIAL AND METHODS: This observational study included 40 patients with first ever STEMI of the anterior wall. LV reverse remodeling was defined as the reduction of left ventricular end-systolic volume (ΔLVESV) by ≥ 10% in 3D transthoracic echocardiography (3D-TTE) at 3-month follow-up. 3D-TTE and speckle tracking imaging were performed during index hospitalization, while 3D-TTE and cardiac magnetic resonance (CMR) were performed at 3 months following the procedure. Patients were followed up for a median time of 3.4 years in order to evaluate major adverse cardiovascular events. RESULTS: = 0.07). CONCLUSIONS: Development of reverse modeling in patients with optimal revascularization and tailored pharmacotherapy is relatively high. Further studies are warranted in order to adjudicate its prognostic role for the prediction of adverse events.
No takes yet. Share an insight, caveat, or question.
Grabka et al. (2018) conducted an observational in Anterior wall ST-segment elevation acute myocardial infarction (STEMI) (n=40). Left ventricular reverse remodeling vs. No left ventricular reverse remodeling was evaluated on Major adverse cardiovascular events (MACE) (p=0.07). Left ventricular reverse remodeling occurred in 37.5% of patients with anterior STEMI treated with primary PCI and was associated with a non-significantly lower rate of major adverse cardiovascular events (log-rank p=0.07).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: